Wytwarzanie produktów leczniczych jest dla nas nie tylko kwestia wykonania pewnego procesu technologicznego, ale misją związaną z człowiekiem opartą na wysokim standardzie jakości, bezpieczeństwa i skuteczności leków.
Mamy aktywną i kluczową rolę w podnoszeniu standardów życia codziennego. Sprawiamy, że społeczeństwo jest lepiej poinformowane, zdrowsze, szczęśliwsze i bezpieczniejsze
Sofia, Bulgaria, 29 November 2022 – According to the requirements of Art. 100t of LPOS and in connection with Art. 114, para. 9 of the Law on Public Offering of Securities, “Sopharma” AD announces that today, according to a decision of the Board of Directors dated November 28, 2022, the company concluded the following transaction falling within the scope of Art. 114, para. 2 of the LPOS:
“Sopharma” AD as a Lessee, concluded Annex № 1 to the Lease Agreement dated March 1, 2022 with “Sopharma Imoti” REIT, UIC 175059266.
Sofia, Bulgaria, November 28, 2022 - According to the requirements of Art. 100t of the LPOS, the Board of Directors of "Sopharma" AD announces that on November 28, 2022, "Sopharma" AD received a tender offer registered with the Commission for Financial Supervision from "DONEV INVESTMENTS HOLDING" AD - a shareholder, directly owning 37,600,000 ordinary, dematerialized shares with voting rights, representing 27.89% of the capital and votes in the GMS of "SOPHARMA" AD, on the basis of Art.
Sofia, Bulgaria, November 7, 2022 – According to the requirements of art. 100t of LPOS, “Sopharma” AD notifies that for October 2022 the Company recorded a increase in sales of 30% compared to the same month of the previous year, incl. 13% decrease in domestic sales and 58% increase in export sales.
For the ten months since the beginning of the year the revenues from sales of products increase by 19%, incl. 12% increase of sales for the domestic market and 23% increase in export sales.